Please login to the form below
Cubist
This page shows the latest Cubist news and features for those working in and with pharma, biotech and healthcare.
Gates’ non-profit biotech for poverty diseases sets out its stall at BIO
Cubist Pharma - as head of translational discovery.
Latest news
-
CHMP backs AZ's 'superbug' antibiotic product
AZ is one company that continued to be active in this area, alongside a handful of others such as GlaxoSmithKline and smaller players such as Cubist (now part of Merck
-
Pfizer signs high-level deal with GPCR specialist Heptares
It also has collaborations in place with AstraZeneca (AZ), Merck &Co's Cubist unit, MorphoSys and Takeda.
-
Merck defeated in antibiotic patent case in US
Merck pressed ahead with the Cubist acquisition regardless, closing the deal in the first quarter of the year. ... Nevertheless, if Cubicin succumbs to generic competition early it will lend weight to the arguments of investors who have claimed Merck
-
Merck prepares filings for Clostridium antibody
Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa
-
Merck hopes for another Keytruda with new immunotherapy deal
Merck also said it expects to see an increase in overall revenue from its recent $8.4bn purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin, which made $480m.
More from news
Approximately 12 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
A rare talent
Unconventionally experienced. Sebastian joined Shire from Cubist, whose commercial operations for the UK, Ireland and Nordics he established to launch two novel antibiotics.
-
Pharma deals in February 2015
platform. This has been rewarded over the years by a string of research alliances with companies including AstraZeneca, MedImmune, Novartis, Takeda and Cubist (now Merck &Co), as well as an extensive
-
Curbing the rise of drug resistance
The KPMG report urges governments and global life sciences businesses to invest more in antibiotic research and development, yet, the recent acquisition of Cubist Pharmaceuticals by Merck &Co.
-
Cubist: Meeting the challenge in antibiotics
Patrick Vink on Cubist Pharmaceuticals’ ambitions in anti-infectives, which have attracted the attention of Merck &Co. ... Cubicin (daptomycin) is Cubist's leading product with net revenues of $256.7m for the third quarter of 2014.
-
Pharma deals during December 2014
Cubist itself has been growing over the last few years with a number of acquisitions. ... Under this ruling, four out of five Cubist patents protecting Cubicin were invalidated.
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Constellation Pharmaceuticals appoints Emma Reeve as CFO
Prior to that he spent ten years at Cubist Pharmaceuticals, Biogen and Covance.
-
Nabriva Therapeutics appoints new chief commercial officer
Prior to serving MSD as its acting vice president, global brand leader anti-infective portfolio, he was vice president, international marketing for the anti-infectives portfolio at Cubist Pharmaceuticals.
-
Caligor Rx appoints Michael Dallmann as director of strategic planning
He brings experience from Cubist Pharmaceuticals and Peninsula Pharmaceuticals. New Jersey-based Caligor Rx has named Michal Dallman to the newly-created role of as director of strategic planning. ... Dallmann - who has over two decades of pharmaceutical
-
Cubist’s Dr Lorianne Masuoka jumps ship to InVivo
Comes amidst MSD’s recent takeover of the antibiotic specialist. InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... Prior to her time at Cubist, she served in various roles of
-
Cubist picks Robert Perez as its new CEO
Bonney, who will take over as chair of the company's board of directors, has led Cubist since 2003 having joined the company a year earlier as chief operating officer. ... Cubist's ambitions have been seen with a number of drug launches as well as its
More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- A new era for UK-Japanese scientific research relations
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
